Developing a Vaccine to Protect Against Pandemic Influenza Public Statement by GlaxoSmithKline 27...
-
Upload
emory-jones -
Category
Documents
-
view
213 -
download
0
description
Transcript of Developing a Vaccine to Protect Against Pandemic Influenza Public Statement by GlaxoSmithKline 27...
![Page 1: Developing a Vaccine to Protect Against Pandemic Influenza Public Statement by GlaxoSmithKline 27 February 2007.](https://reader036.fdocuments.us/reader036/viewer/2022082908/5a4d1b397f8b9ab05999ddf5/html5/thumbnails/1.jpg)
Developing a Vaccine to Protect Against Pandemic Influenza
Public Statement by GlaxoSmithKline
27 February 2007
![Page 2: Developing a Vaccine to Protect Against Pandemic Influenza Public Statement by GlaxoSmithKline 27 February 2007.](https://reader036.fdocuments.us/reader036/viewer/2022082908/5a4d1b397f8b9ab05999ddf5/html5/thumbnails/2.jpg)
2
Challenges for a Pandemic Vaccine
The population is immunologically naïve to a pandemic virus
Reactive production of a pandemic vaccine, even with a large capacity increase, could leave most people unprotected
![Page 3: Developing a Vaccine to Protect Against Pandemic Influenza Public Statement by GlaxoSmithKline 27 February 2007.](https://reader036.fdocuments.us/reader036/viewer/2022082908/5a4d1b397f8b9ab05999ddf5/html5/thumbnails/3.jpg)
3
GSK’s Position
Advance production and stockpiling are the foundation of pandemic preparedness
The ideal vaccine to support this approach:
Effective against drift variants
Antigen-sparing
Can be stockpiled (shelf-life)
![Page 4: Developing a Vaccine to Protect Against Pandemic Influenza Public Statement by GlaxoSmithKline 27 February 2007.](https://reader036.fdocuments.us/reader036/viewer/2022082908/5a4d1b397f8b9ab05999ddf5/html5/thumbnails/4.jpg)
4
Effect of GSK’s Adjuvant System on Immune Response to H5N1 Vaccine
Since baseline HI titersare largely <10,rates of ‘seroprotection” and seroconversion are essentially equal
CHMP/CBER 70% criterion
0
10
20
30
40
50
60
70
80
90
100
No Adjuvant
With Adjuvant
3.8 ug 7.5 ug 15 ug 30 ug
% o
f Sub
ject
s (9
5% C
I)
No Adjuvant
With Adjuvant
No Adjuvant
With Adjuvant
No Adjuvant
With Adjuvant
ClinicalTrials.gov identifier: NCT00309634
![Page 5: Developing a Vaccine to Protect Against Pandemic Influenza Public Statement by GlaxoSmithKline 27 February 2007.](https://reader036.fdocuments.us/reader036/viewer/2022082908/5a4d1b397f8b9ab05999ddf5/html5/thumbnails/5.jpg)
5
Regulations for Pre-Pandemic Vaccines
Europe’s CHMP has issued comprehensive guidanceEfficacy surrogate → HI antibody response to vaccineSupportive data for cross-protection:
Cross-reactive neutralizing antibody responsesProtection in ferret modelAbility of vaccination to support a booster-response upon vaccination with a drifted strain
GSK filed a EU license application for its pre-pandemic vaccine 29 Jan 07GSK is discussing with FDA what evidence will enable a U.S. license application
![Page 6: Developing a Vaccine to Protect Against Pandemic Influenza Public Statement by GlaxoSmithKline 27 February 2007.](https://reader036.fdocuments.us/reader036/viewer/2022082908/5a4d1b397f8b9ab05999ddf5/html5/thumbnails/6.jpg)
6
GSK’s Pre-Pandemic Vaccine Development Plan
Conduct pivotal trials of our vaccine with adjuvant under an IND in 2007 and file a U.S. license application
While application under review, extend safety database, generate data for supplemental application:
Pediatric indication
General use prophylaxis of all ages